RenovoRx’ Differentiated Targeted Drug Delivery Platform Addressing Hypovascular cancers
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
RenovoRx’ Differentiated Targeted Drug Delivery Platform Addressing Hypovascular cancers
-
Narrated by:
-
By:
About this listen
Send us a text
In this episode of WTR Small-Cap Spotlight, host Tim Gerdeman and analyst Robert Sassoon speak with Shaun Bagai, CEO of RenovoRx (NASDAQ: RNXT). The company is pioneering targeted oncology therapies and commercializing RenovoCath™, an FDA-cleared multi-specialty local drug delivery device for high unmet needs. We discuss the innovation and advantages of its TAMP™ (Trans-Arterial Micro-Perfusion) platform—powered by the proprietary dual-balloon catheter—and how it sets RenovoRx apart in treating hard-to-reach hypovascular tumors like pancreatic cancer. The conversation also covers RenovoCath’s commercialization strategy and key milestones in its Phase 3 clinical trial aimed at proving the platform’s delivery superiority over the current standard of care.